PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Parasite lost

By targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria

2013-11-28
(Press-News.org) Contact information: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Parasite lost By targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria

Using advanced methodologies that pit drug compounds against specific types of malaria parasite cells, an international team of scientists, including researchers at the University of California, San Diego School of Medicine and the Genomics Institute of the Novartis Research Foundation, have identified a potential new weapon and approach for attacking the parasites that cause malaria.

Their findings are published in the November 27, 2013 advanced online publication of Nature.

Despite advances in prevention and treatment in recent years, malaria remains one of the world's great infectious scourges. In 2010, according to the World Health Organization, there were an estimated 219 million cases globally and 660,000 deaths, mostly among African children.

The disease is caused by Plasmodium parasites, which are transmitted to humans by the infectious bite of an Anopheles mosquito. Plasmodium vivax and Plasmodium falciparum are the most problematic of the parasite species. The former is the most widespread globally; the latter most deadly.

Principal investigator Elizabeth A. Winzeler, PhD, professor in the Division of Pharmacology and Drug Discovery, Department of Pediatrics and director of translational research at the UC San Diego Health Sciences Center for Immunity, Infection & Inflammation, and colleagues found a key metabolic enzyme (phosphatidylinositol 4-kinase or PI4K) that is used for intracellular development by Plasmodium species at each stage of infection in the vertebrate host.

The discovery could have significant ramifications for eventually eradicating malaria as a global disease. "Elimination efforts are more effective with better tools and infrastructure," said Winzeler. "Clearly we have better infrastructure and communication now than we had in the 1960s. To make more progress, though, we need more effective drugs."

A major obstacle has been the developmental nature of the P. vivax parasite. While some antimalarial drugs effectively kill P. vivax as it circulates in the host's bloodstream, the parasite also produces an early-stage form called a hypnozoite that can lie dormant and undetected in the livers of infected persons for years before reinitiating development and triggering relapse.

"Most drugs selectively work on certain stages of the (parasite) lifecycle, but not all stages," said Case McNamara, PhD, the study's first author and a researcher at the Genomics Institute of the Novartis Research Foundation in San Diego. "Therefore, inhibitors of this drug target have the potential to not only cure individuals of a malaria infection, but to also prevent infections and even block transmission of the parasite back to the mosquito."

Currently, the only licensed antimalarial drug capable of fully cleansing hidden hypnozoites and eliminating the possibility of relapse – known as the "radical cure" – is primaquine, a drug first tested in the 1940s and licensed by the Food and Drug Administration in 1952.

But primaquine has significant adverse side effects and shortcomings, according to Winzeler, most notably that it can cause life-threatening anemia in people with a specific inherited metabolic enzyme deficiency frequently found in malaria-endemic regions.

"In addition, it may not work all of the time and it requires a prolonged dosing schedule, up to 14 days, which means compliance is an issue. People often do not take the full dose," Winzeler said. "Primaquine is an old drug and it's not clear that it would ever be licensed in today's regulatory environment."

Primaquine was developed "by simply injecting a lot of compounds into monkeys and seeing which compound cured malaria infections," said Winzeler. It was later tested in humans using prisoners.

The new approach is far more finely tuned, based on a series of detailed cellular assays that seek to model different parasite lifecycle stages in miniature test tubes. The researchers looked for the rare compound class that had activities in all parasite stages, but no activity against human cells and which was also drug-like. A new chemical class, called imidazopyrazines, possessed these properties. The researchers then identified the protein target of these compounds as PI4K.

"(Dr. Winzeler) had a very creative and powerful idea to help identify malaria drug targets," said McNamara. "By patiently evolving drug-resistant parasites against the drug of interest, we can probe the genome for the changes responsible for conferring resistance.

"Fortunately, malaria parasites will often try to alter the drug target in subtle ways to prevent the drug from working effectively. So, by identifying these changes we, in turn, identify the drug target. This approach has worked so well that it has quickly become a standard technique in our field to help study and characterize all new antimalarials."

Because PI4K is also found in humans, Winzeler said the next challenge is to develop a superior drug that continues to discriminate between the parasite and human versions of this enzyme. “Since we know the identity of this protein and will hopefully soon solve its structure, this task will be much easier,” she said.”



INFORMATION:

Co-authors include Marcus C.S. Lee, Santha Kumar and Philipp P. Henrich, Department of Microbiology & Immunology, Columbia University; Chek Shik Lim, Siau Hoi Lim, Oliver Simon, Bryan K.S. Yeung, Christophe Bodenreider and Thierry T. Diagana, Novartis Institutes for Tropical Disease, Singapore; Jason Roland, Arnab K. Chatterjee, Susan L. McCormack, Kerstin Gagaring, Maureen Ibanez, Nobutaka Kato, Kelli L. Kuhen, Advait Nagle, David M. Plouffe, Badry Bursulaya, David C. Tully and Richard J. Glynne, Genomics Institute of the Novartis Research Foundation, San Diego; Micah J. Manary and Stephan Meister, Department of Pediatrics, UCSD; Anne-Marie Zeeman and Clemens H.M. Kocken, Department of Parasitology, Biomedical Primate Research Centre, The Netherlands; Koen J. Dechering and Martijn Timmerman, TropIQ Health Sciences, The Netherlands; Christoph Fischeli, Swiss Tropical and Public Health Institute; Mathias Rottmann, Swiss Tropical and Public Health Institute and University of Basel; Lucia Rameh, Department of Medicine, Boston University; Joerg Trappe and Dorothea Haasen, Novartis Institutes for BioMedical Research; Robert W. Sauerwein, TropIQ Health Sciences and Department of Medical Microbiology, Radboud University, The Netherlands; Rossarin Suwanarusk and Laurent Renia, Laboratory of Malaria Immunology, Agency for Science Technology and Research, Singapore; Bruce Russell, Laboratory of Malaria Immunology, Agency for Science Technology and Research and Department of Microbiology, National University of Singapore; Francois Nosten, Centre for Tropical Medicine, University of Oxford and Shoklo Malaria Research Unite, Mahidol University, Thailand; and David A. Fidock, Department of Microbiology & Immunology, Columbia University and Division of Infectious Diseases, Columbia University Medical Center, NY.

Funding support came, in part, from the Wellcome Trust, the Medicines for Malaria Venture, the Swiss Tropical and Public Health Institute, Columbia University, the Novartis Institute for Tropical Diseases, the Singapore Immunology Network and Horizontal Programme on Infectious Diseases under the Agency for Science Technology and Research, the Bill and Melinda Gates Foundation and the National Institutes of Health (grants R01AI090141, R01085584 and R01079709).



ELSE PRESS RELEASES FROM THIS DATE:

Economic development can only buy happiness up to a 'sweet spot' of $36,000 GDP per person, study finds

2013-11-28
Economic development can only buy happiness up to a 'sweet spot' of $36,000 GDP per person, study finds Economists have shed light on the vexed question of whether economic development can buy happiness – and it seems that life satisfaction actually dips ...

Scientists develop way to successfully give nanoparticle therapeutics orally

2013-11-28
Scientists develop way to successfully give nanoparticle therapeutics orally Findings will allow for more targeted, convenient drug delivery to treat chronic diseases, like diabetes Boston, MA – Pop a pill or be poked by a ...

Making a gem of a tiny crystal

2013-11-28
Making a gem of a tiny crystal Slowly cooled DNA transforms disordered nanoparticles into orderly crystal Nature builds flawless diamonds, sapphires and other gems. Now a Northwestern University research team is the first to build near-perfect single crystals ...

The good news about the global epidemic of dementia

2013-11-28
The good news about the global epidemic of dementia New England Journal of Medicine perspective highlights effects of education, prevention SEATTLE—It's rare to hear good news about dementia. But that's what a New England Journal of Medicine Perspective article ...

Physicists find a way to study coldest objects in the universe

2013-11-28
Physicists find a way to study coldest objects in the universe They are the coldest objects in the Universe and are so fragile that even a single photon can heat and destroy them. Known as Bose-Einstein condensates (BECs) and consisting of just a cluster ...

Improved safety measures by mental health service providers help to reduce suicide rates

2013-11-28
Improved safety measures by mental health service providers help to reduce suicide rates Mental health service providers looking after patients at risk of suicide need to reduce absconding on in-patient wards and boost specialist community services ...

Global study reveals pandemic of untreated cancer pain due to over-regulation of pain medicines

2013-11-28
Global study reveals pandemic of untreated cancer pain due to over-regulation of pain medicines A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world's population live in countries where ...

Are you carrying adrenal Cushing's syndrome without knowing it?

2013-11-28
Are you carrying adrenal Cushing's syndrome without knowing it? In light of new research, Dr. Andre Lacroix suggests genetic screening to find 'silent carriers' Genetic research that will be published tomorrow in the New England Journal of Medicine ...

Pills of the future: Nanoparticles

2013-11-28
Pills of the future: Nanoparticles CAMBRIDGE, MA -- Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so ...

New research shows pre-existing diabetes in pregnancy greatly increases the risk of death of the fetus or infant child

2013-11-28
New research shows pre-existing diabetes in pregnancy greatly increases the risk of death of the fetus or infant child New research shows that pre-existing diabetes in pregnant women greatly increases the risk of death of their unborn fetus by around four-and-a-half ...

LAST 30 PRESS RELEASES:

Menopause drug reduces hot flashes by more than 70%, international clinical trial finds

FGF21 muscle hormone associated with slow ALS progression and extended survival

Hitting the right note: The healing power of music therapy in the cardiac ICU

Cardiovascular disease risk rises in Mexico, despite improved cholesterol control

Flexible optical touch sensor simultaneously pinpoints pressure strength and location

Achalasia diagnosis simplified to AI plus X-ray

PolyU scholars pioneer smart and sustainable personal cooling technologies to address global extreme heat

NIH grant aims for childhood vaccine against HIV

Menstrual cycle and long COVID: A relation confirmed

WMO report on global water resources: 2024 was characterized by both extreme drought and intense rainfall

New findings explain how a mutation in a cancer-related gen causes pulmonary fibrosis

Thermal trigger

SNU materials science and engineering team identifies reconstruction mechanism of copper alloy catalysts for CO₂ conversion

New book challenges misconceptions about evolution and our place in the tree of life

Decoding a decade of grouper grunts unlocks spawning secrets, shifts

Smart robots revolutionize structural health monitoring

Serum-derived hsa_circ_101555 as a diagnostic biomarker in non-hepatocellular carcinoma chronic liver disease

Korea University study identifies age 70 as cutoff for chemotherapy benefit in colorectal cancer

Study explores brain cell communication called ‘crosstalk’

4 beer and wine discoveries

Massage Therapy Foundation awards $299,465 research grant to Children’s Hospital of Philadelphia

Chung-Ang University develops chloride-resistant Ru nanocatalysts for sustainable hydrogen production from seawater

Afghanistan’s August 2025 earthquake reveals the cost of international isolation, UN scientists warn

Shortlist announced for Panmure House Prize

Small nuclear RNA base editing a safer alternative to CRISPR, UC San Diego researchers find

Can Hayabusa2 touchdown? New study reveals space mission’s target asteroid is tinier and faster than thought

Millisecond windows of time may be key to how we hear, study finds

Graz University of Technology opens up new avenues in lung cancer research with digital cell twin

Exoplanets are not water worlds

Study shows increasing ‘healthy competition’ between menu options nudges patients towards greener, lower-fat hospital food choices

[Press-News.org] Parasite lost
By targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria